Estimation of the ED95 of Intrathecal Hyperbaric Prilocaine 2% With Sufentanyl for Scheduled Cesarean Delivery
Launched by CENTRE HOSPITALIER UNIVERSITAIRE SAINT PIERRE · Jan 26, 2017
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • American Society of Anesthesiologists physical status (ASA) \< III
- • Age 18-40 year
- • Body Weight \<100 kg
- • Height between 155 and 175 cm
- • Gestational age\>37 SA
- • Elective cesarean delivery
- • Singleton pregnancy
- • Non complicated pregnancy
- • Signed informed consent obtained prior to any study specific assessments and procedures
- Exclusion Criteria:
- • Twin pregnancy
- • History of 2 cesarean section or more
- • Diabetes and gestational diabetes
- • Placenta praevia
- • Congenital foetal abnormality
- • Patient in labour
- • Membrane rupture
- • Known allergy to local anaesthetics
- • Disagreement of the patient
- • Pregnancy-induced hypertension
- • Pre eclampsia and eclampsia
About Centre Hospitalier Universitaire Saint Pierre
The Centre Hospitalier Universitaire Saint Pierre (CHU Saint Pierre) is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and high-quality patient care. Located in Brussels, Belgium, this institution is known for its multidisciplinary approach, integrating cutting-edge medical practices with comprehensive training for healthcare professionals. With a focus on improving patient outcomes, CHU Saint Pierre actively sponsors and conducts a wide range of clinical trials, fostering collaboration among researchers, clinicians, and industry partners to address pressing medical needs and enhance therapeutic options. Its commitment to ethical standards and rigorous scientific methodologies ensures the integrity and reliability of its research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels Capital Region, , Belgium
Patients applied
Trial Officials
Panayota Kapessidou, MD,PhD
Study Director
University Hospital Saint-Pierre (CHU Saint-Pierre), Université Libre de Bruxelles (ULB)
Philippe Goffard, MD
Principal Investigator
University Hospital Saint-Pierre (CHU Saint-Pierre), Université Libre de Bruxelles (ULB)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials